Actively Recruiting
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
Led by Centessa Pharmaceuticals (UK) Limited · Updated on 2026-02-25
212
Participants Needed
1
Research Sites
70 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
CONDITIONS
Official Title
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy males or females as determined by assessments at the Screening Visit
- Participants must be at least 18 years old and no more than 60 years old at the Screening
You will not qualify if you...
- Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease
- History of seizure disorder or any other condition that increases the risk of seizure
- Clinically significant sleep disorder, including insomnia or sleep apnea
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Celerion
Lincoln, Nebraska, United States, 68502
Actively Recruiting
Research Team
O
ORX489 Centessa Program Lead ORX489 Centessa Program Lead
CONTACT
C
Celerion Program Lead CA49982 United States, Nebraska [Recruiting]
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here